Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $13 from $12 and keeps a Neutral rating on the shares after its Q4 earnings beat. The firm has updated its model to reflect the anticipated regulatory exclusivity period and terminal rate of 0% to reflect potential generic entry after 2032 and uncertainty over the company’s consumer marketing campaigns, the analyst tells investors in a research note.